Antiangiogenic activity of chemopreventive drugs

International Journal of Biological Markers

Volumn 18, Issue 1, 2003, Pages 70-74

  Pfeffer, Ulrich ^a   Ferrari, N ^a   Morini, M ^a   Benelli, R ^a   Noonan, D M ^a   Albini, Adriana ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis; Antioxidants; Chemoprevention; Inflammation

Indexed keywords

ACETYLCYSTEINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FENRETINIDE; FLAVONOID; GREEN TEA EXTRACT; HEPARIN; MATRIGEL; MUCOLYTIC AGENT; PARACETAMOL; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INTOXICATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOXICITY; HIGH RISK PATIENT; HUMAN; METASTASIS; NONHUMAN; PREVENTIVE MEDICINE; STROMA; TUMOR; TUMOR CELL; TUMOR GROWTH;

EID: 0142186748     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5042     Document Type: Conference Paper

References (32)

1. Liotta LA, , Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
2. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
4. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
6. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-65.
7. Majno G. Chronic inflammation: Links with angiogenesis and wound healing. Am J Pathol 1998; 153: 1035-9.
8. Cockett MI, Birch ML, Murphy G, Hart IR, Docherty AJ. Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans 1994; 22: 55-7.
9. Baramova E, Foidart JM. Matrix metalloproteinase family. Cell Biol Int 1995; 19: 239-42.
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
12. Lissoni P, Fugamalli E, Malugani F, et al. Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int J Biol Markers 2000; 15: 308-11.
13. Jiang C, Ganther H, Lu J. Monomethyl selenium - Specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol Carcinog 2000; 29: 236-50.
14. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-90.
15. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. FASEB J 2002; 16: 267-9.
16. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-2.
17. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
18. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
19. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.
20. Oppenheim JJ, Murphy WJ, Chertox O, Schirrmacher V, Wang JM. Prospects for cytokine and chemokine biotherapy. Clin Cancer Res 1997; 3: 2682-6.
21. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-79.
22. Tosetti F, Ferrari N, De Flora S, Albini A. 'Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
23. Benelli R, Vene R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem 2002; 383: 101-5.
24. Dresdale AR, Barr LH, Bonow RO, et al. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 1982; 5: 657-63.
25. De Vries N, De Flora S. N-acetyl-l-cysteine. J Cell Biochem (Suppl) 1993; 17F: 270-7.
26. Camerini T, De Palo G, Mariani L, Marubini E, Costa A, Veronesi U. Accrual issues for chemoprevention trials: The example of the 4-HPR study for the prevention of contralateral breast cancer. Tumori 1999; 85: 299-303.
27. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Chemoprevention of breast cancer: The Italian experience. J Cell Biochem 2000; 77: 84-96.
28. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
29. Albini A, Fontanini G, Masiello L, et al. Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: Inhibition of KS-like lesions by TIMP-2. AIDS 1994; 8: 1237-44.
30. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002; 2: 281-292.
31. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-52.
32. Albini A, Paglieri I, Orengo G, et al. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. Aids 1997; 11: 713-21.